Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

Conclusion:
Natalizumab is superior to fingolimod in RRMS patients non-responding to first-line agents.

Source: Multiple Sclerosis - September 6, 2016 Category: Neurology Authors: Baroncini, D., Ghezzi, A., Annovazzi, P. O., Colombo, B., Martinelli, V., Minonzio, G., Moiola, L., Rodegher, M., Zaffaroni, M., Comi, G. Tags: Original Research Papers Source Type: research